AMG 745

an antimyostatin peptibody that consists of a human Fc fragment used to a myostatin-neutralizing peptide

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Prostatic Neoplasms (Prostate Cancer) 10/01/2014 - "The objective of the study was to evaluate the safety, pharmacokinetics, and muscle efficacy of AMG 745 in men undergoing ADT for nonmetastatic prostate cancer. " 10/01/2014 - "doses of AMG 745 were well tolerated and were associated with increased LBM and decreased fat in the men receiving ADT for nonmetastatic prostate cancer. "
2.	Fatigue 10/01/2014 - "Rates of adverse events (AMG 745 vs placebo) were the following: diarrhea (13% vs 9%), fatigue (13% vs 4%), contusion (10% vs 0%), and injection site bruising (6% vs 4%). "
3.	Diarrhea 10/01/2014 - "Rates of adverse events (AMG 745 vs placebo) were the following: diarrhea (13% vs 9%), fatigue (13% vs 4%), contusion (10% vs 0%), and injection site bruising (6% vs 4%). "
4.	Contusions 10/01/2014 - "Rates of adverse events (AMG 745 vs placebo) were the following: diarrhea (13% vs 9%), fatigue (13% vs 4%), contusion (10% vs 0%), and injection site bruising (6% vs 4%). "
5.	Atrophy 10/01/2014 - "RESULTS support further investigation of AMG 745 in clinical settings with muscle loss and atrophy."